^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NUMARZU-001

    i
    Other names: NUMARZU-001, PD1+TILs infusion
    Associations

    News

    Trials
    Company:
    Hospital Clinic of Barcelona
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    12ms
    TILS001: Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Fundacio Clinic Barcelona | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2024 --> Nov 2025
    Enrollment open • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1)
    |
    HER-2 negative • PD-1 expression • PGR expression
    |
    NUMARZU-001
    over2years
    TILS001: Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Fundacio Clinic Barcelona
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1)
    |
    HER-2 negative • PD-1 expression • PGR expression
    |
    NUMARZU-001